GLP-1 Drug Interactions: A Prescriber's Reference

GLP-1 receptor agonists have a relatively favorable drug interaction profile compared to many other medications, but there are several clinically significant interactions that prescribers need to know. This reference covers the most important interactions and how to manage them.

GLP-1 agonists slow gastric emptying. This affects the absorption of orally administered medications, particularly those with narrow therapeutic windows or time-sensitive absorption requirements.

Oral medications with time-sensitive absorption: For medications that need to be absorbed quickly (e.g., oral hypoglycemics taken with meals, certain antibiotics), slowed gastric emptying can delay the onset of action. This is generally not clinically significant for most medications but should be considered.

Oral contraceptives: The FDA labeling for some GLP-1 agonists recommends taking oral contraceptives at least 1 hour before or 4 hours after the GLP-1 injection to minimize the effect of slowed gastric emptying on contraceptive absorption. Counsel patients on this interaction.

Cyclosporine: Slowed gastric emptying can affect cyclosporine absorption. Monitor cyclosporine levels in transplant patients starting GLP-1 therapy.

The most clinically significant interaction is with insulin. GLP-1 agonists lower blood glucose through multiple mechanisms (increased insulin secretion, decreased glucagon, slowed gastric emptying). When combined with insulin, the risk of hypoglycemia increases.

Management:

• When starting a GLP-1 agonist in a patient on insulin, consider reducing the insulin dose by 10–20%
• Monitor blood glucose more frequently during the titration period
• Educate patients on hypoglycemia recognition and treatment
• Adjust insulin dose based on glucose monitoring

Sulfonylureas (glipizide, glyburide, glimepiride) stimulate insulin secretion independently of blood glucose. Combined with GLP-1 agonists, the risk of hypoglycemia increases.

Management:

• Consider reducing the sulfonylurea dose when starting a GLP-1 agonist
• Monitor blood glucose
• Educate patients on hypoglycemia risk

Meglitinides (repaglinide, nateglinide) have a similar interaction profile to sulfonylureas.

Beta-blockers can mask the symptoms of hypoglycemia (tachycardia, tremor) while not masking sweating. Patients on beta-blockers who are also on GLP-1 agonists with insulin or sulfonylureas need to be counseled about this masking effect.

GLP-1 agonists reduce blood pressure by 3–5 mmHg on average. In patients on antihypertensive medications, this can lead to excessive blood pressure reduction. Monitor blood pressure when starting GLP-1 therapy and consider dose adjustments.

GLP-1 agonists can affect warfarin absorption through their effects on gastric emptying. Monitor INR more frequently when starting or stopping GLP-1 therapy in patients on warfarin.

GLP-1 agonists can cause acute kidney injury in some patients, particularly those who are volume-depleted due to GI side effects (nausea, vomiting, diarrhea). In patients on medications that are renally cleared (metformin, certain antibiotics, lithium), acute kidney injury can lead to drug accumulation.

Management:

• Ensure adequate hydration during GLP-1 therapy
• Monitor renal function in patients on renally-cleared medications
• Hold renally-cleared medications if significant GI side effects occur

Metformin is commonly used alongside GLP-1 agonists in patients with type 2 diabetes. The combination is generally well-tolerated and complementary. However, if GI side effects from GLP-1 therapy lead to dehydration and acute kidney injury, metformin accumulation can cause lactic acidosis. Counsel patients to stay hydrated and hold metformin if they develop significant GI symptoms.

GLP-1 agonists can affect levothyroxine absorption through their effects on gastric emptying. Monitor thyroid function in patients on levothyroxine who start GLP-1 therapy.

Alcohol can increase the risk of hypoglycemia in patients on GLP-1 agonists with insulin or sulfonylureas. Counsel patients to limit alcohol intake and to eat when drinking.

1. Review the full medication list before starting GLP-1 therapy
2. Identify hypoglycemia risk — adjust insulin and sulfonylurea doses proactively
3. Counsel on oral contraceptive timing if applicable
4. Monitor blood pressure in patients on antihypertensives
5. Monitor INR in patients on warfarin
6. Ensure hydration to minimize renal risk
7. Document the interaction review in the medical record

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should review current prescribing information and use clinical judgment.